Baxter International Inc. Files 8-K
Ticker: BAX · Form: 8-K · Filed: Nov 7, 2024 · CIK: 10456
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: BAX
TL;DR
Baxter filed a routine 8-K on Nov 7, 2024. No major news.
AI Summary
Baxter International Inc. filed an 8-K on November 7, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this date.
Why It Matters
This filing serves as a routine update for investors, indicating that Baxter International Inc. has submitted required disclosures to the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not indicate any new risks or material adverse events.
Key Players & Entities
- Baxter International Inc. (company) — Registrant
- November 7, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing by Baxter International Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits as of November 7, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is November 7, 2024.
In which state was Baxter International Inc. incorporated?
Baxter International Inc. was incorporated in Delaware.
What is Baxter International Inc.'s IRS number?
Baxter International Inc.'s IRS number is 36-0781620.
What is Baxter International Inc.'s standard industrial classification code?
Baxter International Inc.'s standard industrial classification code is 3841, for Surgical & Medical Instruments & Apparatus.
Filing Stats: 927 words · 4 min read · ~3 pages · Grade level 14.1 · Accepted 2024-11-07 08:49:19
Key Financial Figures
- $1.00 — ange on which registered Common Stock, $1.00 par value BAX (NYSE) New York Stock Exc
Filing Documents
- bax-20241107.htm (8-K) — 31KB
- exhibit991.htm (EX-99.1) — 25KB
- exhibit991001.jpg (GRAPHIC) — 87KB
- exhibit991002.jpg (GRAPHIC) — 105KB
- exhibit991003.jpg (GRAPHIC) — 194KB
- exhibit991004.jpg (GRAPHIC) — 175KB
- exhibit991005.jpg (GRAPHIC) — 177KB
- exhibit991006.jpg (GRAPHIC) — 156KB
- exhibit991007.jpg (GRAPHIC) — 190KB
- exhibit991008.jpg (GRAPHIC) — 167KB
- exhibit991009.jpg (GRAPHIC) — 214KB
- exhibit991010.jpg (GRAPHIC) — 190KB
- exhibit991011.jpg (GRAPHIC) — 205KB
- exhibit991012.jpg (GRAPHIC) — 193KB
- exhibit991013.jpg (GRAPHIC) — 58KB
- exhibit991014.jpg (GRAPHIC) — 87KB
- 0001628280-24-046016.txt ( ) — 3283KB
- bax-20241107.xsd (EX-101.SCH) — 4KB
- bax-20241107_def.xml (EX-101.DEF) — 19KB
- bax-20241107_lab.xml (EX-101.LAB) — 35KB
- bax-20241107_pre.xml (EX-101.PRE) — 20KB
- bax-20241107_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. As previously disclosed, on August 12, 2024, Baxter International Inc., a Delaware corporation (the "Company"), entered into an Equity Purchase Agreement with certain affiliates of Carlyle Group Inc. to sell the Company's Kidney Care business (the "Transaction"), subject to the receipt of customary regulatory approvals and satisfaction of other closing conditions. In connection with the Transaction, the Company determined that its Kidney Care business met the criteria to be classified as held-for-sale in August 2024, and the Company also concluded that the Kidney Care business met the conditions to be reported as a discontinued operation at that time. Accordingly, the Kidney Care business will be reported as a discontinued operation beginning with the Company's condensed consolidated financial statements and notes thereto for the quarter ended September 30, 2024, and the Company's prior period financial position and results of operations will be retroactively adjusted to reflect discontinued operations presentation. To assist investors in comparing the Company's historical financial information and results for the Company's continuing and discontinued operations, Exhibit 99.1 filed with this Current Report on Form 8-K includes a presentation consisting of retrospectively adjusted supplemental unaudited historical financial information for the Company for each of the quarters ended June 30, 2024, March 31, 2024, December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023. The information included in Exhibit 99.1 to this Current Report on Form 8K presents, for informational purposes only, the Company's retrospectively adjusted historical financial results to reflect the impact of presenting the Kidney Care business as a discontinued operation for all periods shown. The presentation of the Kidney Care business as a discontinued operation affects only the manner in which certain financial information was previously repo
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Presentation of Supplemental Historical Financial Information, dated November 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: November 7, 2024 BAXTER INTERNATIONAL INC. By: /s/ Joel T. Grade Name: Joel T. Grade Title: Executive Vice President, Chief Financial Officer and Interim Chief Accounting Officer